Prognostic value of microRNAs in heart failure
A meta-analysis

Jie Yang, MDa, Xue-Song Yang, MMb, Shao-Wei Fan, MMC, Xiao-Yu Zhao, MMc, Chao Li, MMC, Zheng-Yao Zhao, MMd, Hui-Juan Pei, MMC, Lu Qiu, MMC, Xin Zhuang, PhDd, Chuan-Hua Yang, PhDd,*

Abstract
Background: Reported studies have shown that expression levels of microRNAs (miRNAs) are related to survival time of patients with heart failure (HF). A systematic review and meta-analysis were conducted to study circulating miRNAs expression and patient outcome.

Methods: Meta-analysis estimating expression levels of circulating miRNAs in HF patients from January 2010 until June 30, 2018, through conducting online searches in Pub Med, Cochrane Database of Systematic, EMBASE and Web of Science and reviewed by 2 independent researchers. Using pooled hazard ratio with a 95% confidence interval to assess the correlation between miRNAs expression levels and overall survival.

Results: Four relevant articles assessing 19 circulating miRNAs in 867 patients were included. In conclusion, the meta-analysis results suggest that HF patients with low expression of serum miR-1, miR-423-5p, miR-126, miR-21, miR-23, miR-30d, miR-18a-5p, miR-16-5p, miR-18b-5p, miR-27a-3p, miR-26b-5p, miR-30e-5p, miR-106a-5p, miR-233-3P, miR-301a-3p, miR-423-3P, and miR-128 have significantly worse overall survival (P < .05). Among them, miR-18a-5p, miR-18b-5p, miR-30d, miR-30e-5p, and miR-423-5p are strong biomarkers of prognosis in HF.

Abbreviations: CI = confidence interval, HF = heart failure, HR = hazard ratio, miRNA = microRNA.

Keywords: circulating microRNAs, heart failure, meta-analysis, prognosis

1. Introduction
In recent years, circulating microRNAs have received increasing attention in the study of cardiovascular disease, and although they have not yet reached the clinical application stage, they have long been shown to play an important role in most cardiovascular diseases. Accumulating studies recognize that circulating microRNAs (miRNAs) are involved in the molecular mechanisms involved in the pathophysiological processes of coronary atherosclerotic plaques and therefore have potential diagnostic and therapeutic value.[1] For example, miR-17-5p, miR-33a, miR-221, miR-222 were mentioned in 1 paper as useful biomarkers for the diagnosis of atherosclerosis, while miR-200c is a biomarker of atherosclerotic plaque progression and can be used to identify patients at high clinical risk of sclerosis.[2] One study found that circulating miR-122 levels were higher in patients with coronary heart disease (CHD) than in controls, and the authors suggest that serum levels of miR-122 may also be used to differentiate the severity of coronary atherosclerotic lesions.[3] In addition, serum miR-9-3p and miR-144-3p are recognized as the most important functional miRNAs and are the most important signaling pathways in dilated cardiomyopathy (DCM). Huang et al.[4] researched that circulating microRNAs such as miR-9-3p, miR-21-3p, miR-144-3p, and miR-144-5p play a key role in the development and pathogenesis of DCM. Similarly, many miRNAs have been found to be associated with heart failure.

Heart failure (HF) is a complex clinical syndrome caused by cardiac structural and functional disorders, mainly including dyspnea, fatigue, poor exercise tolerance, and fluid retention.[5–7] Heart failure is the final stage in the progression of various cardiovascular diseases, which will greatly reduce the quality of life of patients with it and even endanger their lives.

The morbidity and mortality of heart failure remain high in the world, and heart failure affects nearly 8.823 billion people worldwide, causing 270,000 deaths each year.[8] Gender, age, ethnic, complications, and environment are all influencing factors. According to the US National Health and Nutrition Examination Survey, 5.7 million Americans suffer from heart...
failure, and that number is likely to rise to at least 8 million by 2030.\textsuperscript{[9]} Data show that the prevalence rate of heart failure in developed countries is 1.5% to 2.0%, and that of people over 70 years old is more than 10%. In China, the prevalence rate of heart failure among adults aged 35 to 74 is 0.9%.\textsuperscript{[10]}

Heart failure is a widespread and devastating cardiovascular disease, so it is of great significance to improve the prediction accuracy of heart failure, provide treatment as soon as possible and improve the quality of life of patients with heart failure.

It is reported that expression levels of miRNAs in patients with heart failure are closely related to survival time.\textsuperscript{[11]} The purpose of this study is to assess the prognostic value of circulating miRNAs in HF patients.

1.1. MicroRNAs

The mature miRNAs are short single-stranded endogenous non-coding RNAs (19-23 base pairs in length),\textsuperscript{[11]} which can regulate gene expression after transcription and are widely distributed in plants and animals.\textsuperscript{[12-14]} The formation process of miRNAs is complex. The initial miRNA is transcribed by RNA Polymerase II in the inner rotor or intergenic region and is 1 to 3k in length, and is then developed into pre-miRNAs (stem-structured precursor miRNAs) in the nucleus, under the influence of both Drosha (RNAse III) and Pasha (double-stranded RNA-binding protein). The pre-miRNAs are 70 to 100 nucleotides in length.\textsuperscript{[15-18]}

Exportin-5 mediates the transport of pre-miRNAs from the nucleus into the cytoplasm, which are then cleaved into a double-stranded oligonucleotide (mature double-stranded miRNA) (18-24 nucleotides in length) by the RNase III Dicer.\textsuperscript{[19,20]} miRNAs are important for a number of biological processes, including the regulation of gene expression, and have been implicated in the pathogenesis of various disorders, including cardiovascular diseases.\textsuperscript{[21,22]}

1.2. Heart remodeling and heart failure

Heart failure is typically associated with cardiac remodeling.\textsuperscript{[23]} Cardiac remodeling is a crucial mechanism in HF progression, and is an important factor in cardiac function and prognosis of heart failure.\textsuperscript{[24]} The 3 main features of cardiac remodeling include pathological cardiomyocyte hypertrophy, excessive cardiac extracellular matrix fibrosis, and cardiomyocyte apoptosis.\textsuperscript{[25]} Normal cardiomyocytes are surrounded by collagen fibers and fibroblast which secrete extracellular matrix proteins to cope with pathological stress or myocardial infarction. However, excessive secretion of extracellular matrix proteins leads to myocardial fibrosis, causing mechanical stiffness and contractile dysfunction. Apoptosis of cardiomyocytes can occur through a variety of pathways, accelerating the progression of heart failure.

In addition, studies have shown that heart failure is a prethrombotic state, suggesting that thrombosis and embolism can lead to heart failure events and reduced ejection fraction.\textsuperscript{[26]} It has been reported that heart failure is characterized by autonomic nervous imbalance, sympathetic hyperactivity and parasympathetic dystonia. Oxidative stress is thought to lead to myocardial injury and inflammation, leading to the progression of heart failure.\textsuperscript{[27]}

1.3. Heart failure-related miRNAs

Since the correlation of miRNAs with heart failure was first reported in 2006,\textsuperscript{[28]} numerous miRNAs have been shown to be associated with the development of heart failure, including, miRNA-21, miRNA-1, miRNA-208, miRNA-499, and miRNA-133, among others.\textsuperscript{[29,30]}

2. Methods

All analyses were based on previous published studies, thus no ethical approval and patient consent are required.

2.1. Literature inclusion and exclusion criteria

Eligibility criteria. A randomized controlled trial was conducted using the blinded method or distributed concealment method. Literatures included in English were included only. The study targets were patients diagnosed with heart failure in accordance with the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.\textsuperscript{[31]} The target population was not limited in race, age or gender. The date of publication was limited from January 1, 2010 to June 30, 2018. The data content of the literature includes data analysis tables, hazard ratio (HR), and the corresponding 95% confidence interval (CI), except for the survival curve. The outcome index is the result of the original papers.

Exclusion criteria. Literature from which relevant data could not be extracted or for which full-text articles were not obtained were excluded. Reviews and case reports were all excluded, as were papers that did not meet the inclusion criteria.

2.2. Search strategy

A systematic search in PubMed, EMBASE, Science Web, and Cochrane Database was conducted incorporating literature published from January 2010 to June 2018. The English titles or keywords were heart failure or MiRNA or MicroRNA.

2.3. Literature screening

Documents were screened by 2 researchers independently by reading the title and abstract, followed by the full text if the paper met the inclusion criteria. Only papers that were assigned by both researchers to be included were taken into account. A third researcher would include or exclude papers in the event of discrepancy between the 2 researchers.

2.4. Literature quality evaluation

The 2 researchers assessed the quality of the included studies independently based on the bias risk assessment tool of randomized controlled trials recommended in the Cochrane System Evaluator’s Handbook 5.1.0. In the event of discrepancy, the inclusion or elimination was determined jointly by the 2 researchers or a third researcher decided whether to include or exclude the paper.

2.5. Statistical processing

Data processing and analysis were performed using R 3.6.0 statistical software (GNU system). The HR was used as the effect index, and both the point estimate and the 95% CI of each effect quantity are given. The $I^2$ value (test level $\alpha = 0.05$) was calculated using the Cochrane Q test. Intergroup heterogeneity analysis was performed for each trial using $I^2$ to determine the
heterogeneity. If there was no heterogeneity between the studies (\( P \geq 0.05 \) and \( I^2 \leq 50\% \)), the fixed effect model would be used for analysis, otherwise, the random effect model would be used for analysis and the reasons for heterogeneity would be discussed.

3. Results

3.1. Literature search results and basic information of included studies

The research formula retrieved a total of 4,490 related articles, including 1930 articles from PubMed, 0 articles from EMBASE, 0 articles from Cochrane Database of Systematic Reviews, and 2560 articles searched through other methods. Two thousand three hundred fifty-one articles remained after removing duplications and 1390 articles were retained after the initial title and abstract screening. After reading the full text of 1390 articles, 1030 articles were excluded. A further review of the remaining literature shows that, compared with the latest literature, the 4 articles published from 2015 to 2017 are more suitable for this study. Finally, 4 randomized controlled trials were included,[32–35] with 867 patients involved, including 695 patients in the experimental group and 172 patients in the control group. Nineteen miRNAs in serum from the 4 relevant articles were ultimately assessed.

Figure 1 shows a flow chart of the detailed selection process for this study. The basic information of the literature included in the study is shown in Table 1. Table 2 is a summary of all relevant microRNAs in the retrieved literature; Table 3 is the repetitive microRNAs in Table 2. There are 3 repetitive microRNAs: miR-423-5p, miR-30, and miR-18. As shown in Table 4, low expression of circulating miR-423-5p (HR = 0.66, 95% CI = 0.53-0.84), miR-30 (HR = 0.63, 95% CI = 0.46-0.85), and miR-18 (HR = 0.59, 95% CI = 0.43-0.80) are associated with worse overall survival of heart failure patients. The results of the subgroup analysis (Country, Material, and miRNA) are shown in Table 5.

3.2. Methodological quality evaluation results

The 4 papers included all mentioned randomization, but the specific random methods were mentioned in none of them, nor were they clearly stated.

3.3. Meta-analysis results

All 4 studies reported different miRNAs in heart failure. The effect integration of all the literature’s HR indicators found that \( I^2 = 0\% < 50\% \), indicating that the included literature is not heterogeneous (heterogeneity test \( \chi^2 = 0, P = .96 \)) and requires integration through a fixed effects model, see Figures 2 and 3 for details. Meta-analysis showed that the integrated HR is 0.63 (95% CI, 0.54-0.74).

3.4. Sensitivity analysis

A sensitivity analysis is an important part of a meta-analysis as it aims to determine the robustness of the observed outcomes. If results remain consistent across the sensitivity analysis, the results can be considered robust. A meta-analysis of the remaining
research was performed to evaluate the stability of the results. Through sensitivity analysis, individual studies were eliminated item by item. After the exclusion of each literature, and reintegration of effect values, all were within the CI, and there was no statistical difference compared with that before removal ($I^2=0$), indicating that the sensitivity of the included literature was low, and that the results of this study are stable.

4. Discussion

MicroRNAs are potentially related to the prognosis of heart failure patients. The prognosis of heart failure remains challenging, especially when patients show no significant signs of capacity overload. In such a context, the objectivity, repeatability and reliability of MicroRNA as a biomarker would complement the gaps in research. In addition, potential miRNA biomarkers could guidance of short and long-term therapy in acute heart failure (AHF) patient. Accurate outcome prediction can be used clinically to select the best of several available therapies for AHF patient. Currently, the only recommended biomarkers in this regard are NT–BNP, NT–proBNP, and highly-sensitive C-reactive protein (hs-CRP), whose elevated levels can predict the prognosis of HF patients to some extent, but still have great limitations and cannot accurately determine patient’s prognosis.

There are 3 repetitive miRNAs (miR-30, miR-423-5p, and miR-18) among all relevant microRNAs found in all 4 studies. All these miRNAs are associated with worse overall survival of heart failure patients: miR-423-5p (HR = 0.66, 95% CI = 0.53-0.84), miR-30 (HR = 0.63, 95% CI = 0.46-0.85), and miR-18 (HR = 0.59, 95% CI = 0.43-0.80). For the repetitive miRNAs, different studies find different members of the same family (e.g., miR-18a-5p and miR-18b-5p; miR-30d and miR-30e-5p). However, miR-423-5p is the same for different studies. miR-423-5p is repeatedly used in several studies. The low levels of miR-423-5p in plasma are associated with poor prognosis in HF patients, registering a higher mortality rate. MicroRNAs are expected to greatly improve the accuracy of predicting the outcome of patients with heart failure.

### Table 1
This Table is the collation of the information of the articles included in the article.

| No. | Research topic | Author | Country | Material | Disease |
|-----|----------------|--------|---------|----------|---------|
| 1   | Circulating microRNAs and Outcome in Patients with Acute Heart Failure | Seronde MF, Vausort M, Gayat E, et al | France | Plasma | Acute Heart Failure |
| 2   | The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study | Cakmaka HA, Coskunpinar EB, Iktimur B, et al | Turkey | Serum | Chronic Congestive Heart Failure |
| 3   | Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure | Xiao JJ, Gao RR, Bei YH, et al | China | Serum | Acute Heart Failure |
| 4   | Signature of circulating microRNAs in patients with acute heart failure | Ekaterina S. Ovchinnikova, Daniela Schmitter, Eline L. Vegter, et al | Netherlands | Plasma | Acute Heart Failure |

### Table 2
Summary of miRNA profiles involved in all of the studies, including the HR value and confidence interval of miRNA.

| Study | MicroRNA | HR | LI | Ul |
|-------|----------|----|----|----|
| 1     | miR-423-5p | 0.70 | 0.53 | 0.93 |
| 2     | miR-126 | 0.96 | 0.92 | 1.01 |
| 3     | miR-23 | 0.95 | 0.91 | 1.00 |
| 4     | miR-21 | 0.99 | 0.98 | 1.00 |
| 5     | miR-1 | 1.00 | 0.99 | 1.00 |
| 6     | miR-30d | 0.61 | 0.41 | 0.911 |
| 7     | let-7i-5p | 0.51 | 0.31 | 0.84 |
| 8     | miR-16-5p | 0.67 | 0.42 | 1.07 |
| 9     | miR-18a-5p | 0.62 | 0.42 | 0.91 |
| 10    | miR-18b-5p | 0.54 | 0.33 | 0.88 |
| 11    | miR-26b-5p | 0.92 | 0.60 | 1.40 |
| 12    | miR-27a-3p | 0.73 | 0.48 | 1.09 |
| 13    | miR-30e-5p | 0.65 | 0.41 | 1.02 |
| 14    | miR-106a-5p | 0.67 | 0.44 | 1.01 |
| 15    | miR-128 | 0.80 | 0.51 | 1.25 |
| 16    | miR-199a-3p | 0.79 | 0.52 | 1.20 |
| 17    | miR-233-3p | 0.64 | 0.43 | 0.97 |
| 18    | miR-301a-3p | 0.56 | 0.38 | 0.84 |
| 19    | miR-423-3p | 0.74 | 0.48 | 1.14 |
| 20    | miR-423-5p | 0.59 | 0.38 | 0.92 |
| 21    | miR-652-3p | 0.65 | 0.42 | 1.00 |

### Table 3
Summary of miRNA profiles involved in the studies involved, including the HR value and confidence interval of miRNA.

| Study | MicroRNA | HR | LI | Ul |
|-------|----------|----|----|----|
| 1     | miR-423-5p | 0.70 | 0.53 | 0.93 |
| 2     | miR-423-5p | 0.59 | 0.38 | 0.92 |
| 3     | miR-30d | 0.61 | 0.41 | 0.91 |
| 4     | miR-30e-5p | 0.65 | 0.41 | 1.03 |
| 5     | miR-18a-5p | 0.62 | 0.42 | 0.91 |
| 6     | miR-18b-5p | 0.54 | 0.33 | 0.87 |

### Table 4
The relationship between miRNA expression and clinical outcome.

| Outcome | Study | MicroRNA | HR | LI | Ul |
|---------|-------|----------|----|----|----|
| Low expression-worse OS | 1     | miR-423-5p | 0.7 | 0.53 | 0.93 |
| 4     | miR-423-5p | 0.59 | 0.38 | 0.92 |
| 3     | miR-30d | 0.61 | 0.41 | 0.91 |
| 4     | miR-30e-5p | 0.65 | 0.41 | 1.03 |
| 4     | miR-18a-5p | 0.62 | 0.42 | 0.91 |
| 4     | miR-18b-5p | 0.54 | 0.33 | 0.87 |

HR = hazard ratios of microRNA, LI = the lower limit of 95% confidence interval, Study = according to the number of Table 1 to reduce the length of the table, Ul = the upper limit of 95% confidence interval.
5. Limitations

Some limitations in this study include: Many variables can affect the results of meta-analysis, such as different types of samples (race, plasma, serum, and tissue), disease stage, miRNA method and disconnection value[36]; This analysis only contains English literature, excluding articles of other languages; This study excludes papers that reported survival curves without Hazard Rate (HR) or 95% CI, which reduces the number of included papers[37–39]; Due to the update of the heart failure guidelines, there are differences in the data extraction of heart failure in some literature. We kept the data to try to have a complete summary of the characteristics of the data as much as possible. The inclusion criteria of this work may have excluded relevant miRNA literature of prognostic value. For future clinical and scientific research, this study is the first to systematically assess the association between the expression of circulating miRNAs and disease development in heart failure patients. Future clinical and scientific research may benefit from the findings of this study.

6. Conclusions

In summary, circulating miR-423-5p, miR-126, miR-23, miR-21, miR-1, miR-30d, miR-18a-5p, miR-18b-5p, miR-16-5p, miR-27a-3p, miR-26b-5p, miR-30e-5p, miR-423-3p, miR-301a-3p, miR-233-3p, miR-199a-3p, miR-128, miR-106a-5p, and miR-652-3p demonstrate significant prognostic value. Among them, miR-423-5p, miR-18a-5p, miR-18b-5p, miR-30d, and miR-30e-5p are strong biomarkers of prognosis in HF.
7. Summary and outlook
In recent years, miRNAs and their potential association between microRNA and the onset of heart failure have attracted more and more attention.\(^\text{[40–43]}\) Increasing numbers of studies are addressing the uncertainties on the origins, transport function and mechanisms of action of miRNAs providing important information for future clinical applications. Several miRNAs have been implicated in factors of development and progression of heart failure, such as cardiac hypertrophy, fibrosis, and apoptosis. Studies in miRNAs increase the understanding of heart failure at a deeper pathophysiology level and may provide new means for clinical diagnosis, prognosis and even treatment of heart failure.

Acknowledgments
We thank Edit Ideas for its linguistic assistance.

Author contributions
Conceptualization: Jie Yang, Chuan-Hua Yang.
Data curation: Jie Yang, Xue-Song Yang, Chuan-Hua Yang.
Formal analysis: Jie Yang, Xue-Song Yang.
Funding acquisition: Jie Yang.
Investigation: Shao-Wei Fan, Xiao-Yu Zhao, Chao Li, Zheng-Yao Zhao, Hui-Juan Pei, Lu Qiu.
Methodology: Jie Yang, Xue-Song Yang, Chuan-Hua Yang.
Project administration: Jie Yang, Xue-Song Yang.
Resources: Jie Yang.
Software: Jie Yang.
Supervision: Jie Yang, Xue-Song Yang, Chuan-Hua Yang.
Validation: Jie Yang.
Visualization: Jie Yang.
Writing – original draft: Jie Yang, Xue-Song Yang, Shao-Wei Fan, Xiao-Yu Zhao, Chao Li, Zheng-Yao Zhao, Hui-Juan Pei, Lu Qiu, Xin Zhuang.
Writing – review & editing: Xin Zhuang, Chuan-Hua Yang, Jie Yang.

References
[1] Ali Sheikh MS, Alduraywish A, Almaeen A, et al. Therapeutic value of miRNAs in coronary artery disease. Oxid Med Cell Longev 2021; 2021:1–16.
[2] Soler-Botija C, Gálvez-Montón C, Bayés-Genís A. Epigenetic biomarkers in cardiovascular diseases. Front Genet 2019;10:930. https://doi.org/10.3389/fgene.2019.00930.
[3] Wang YL, Yu W. Association of circulating microRNA-122 with presence and severity of atherothrombotic lesions. PeerJ 2018;6:e5218. https://doi.org/10.7717/peerj.5218.
[4] Huang W, Chen S, Huang J, et al. Integrated analysis of hub genes and miRNAs in dilated cardiomyopathy. Biomed Res Int 2020;2020:1–14.
[5] Lindenfeld J, Albert NM, Boehmer JP, et al. HPSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010;16:e1–94.
[6] Michalska-Kasziak M, Bielecka-Dabrowa A, von Haeliing S, Anker SD, Rydz J, Banach M. Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview. Arch Med Sci 2018;14:890–909.
[7] Ott-Orisan A, Lannear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev 2014;22:193–8.
[8] Dyavaranapalli J, Hora AJ, Escobar JB, et al. Chemogenetic activation of intracardiac cholinergic neurons improves cardiac function in pressure overload-induced heart failure. Am J Physiol Heart Circ Physiol 2020;319:H414–12.
[9] Abu MK, Singal A, Menon R, et al. Early enteral nutrition therapy in congenital cardiac repair postoperatively: a randomized, controlled pilot study. Ann Card Anaesth 2016;19:653–61.
[10] Li S. Advances in epidemiology, pathophysiology and prognosis of senile heart failure. Chin J Geriatric Cardiov Cerebrovasc Dis 2021;10:23:318–20.
[11] Shah P, Bristow MR, Port JD. MicroRNAs in heart failure, cardiac transplantation, and myocardial recovery: biomarkers with therapeutic potential. Curr Heart Fail Rep 2017;14:454–64.
[12] Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853–8.
[13] Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 2001;294:858–62.
[14] Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862–4.
[15] Cai X, Hagedorn CH, Cullen BR. Human microRNAs are processed from capped, polyadenylated transcripts that can also function as miRNAs. RNA 2004;10:1957–66.
[16] Lee Y, Kim M, Han J, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051–60.
[17] Godnic I, Zorc M, Jevinsen Skok D, et al. Genome-wide and species-wide in silico screening for intragenic microRNAs in human, mouse, and chicken. PLoS One 2013;8:e65165. https://doi.org/10.1371/journal.pone.0065165.
[18] Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004;14:1902–10.
[19] Bohnsack MT, Czapinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004;10:185–91.
[20] Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17:3011–6.
[21] Murach KA, McCarthy JJ. MicroRNAs, heart failure, and aging: potential interactions with skeletal muscle. Heart Fail Rev 2017;22:209–18.
[22] Bronze-da-Rocha E. MicroRNAs expression profiles in cardiovascular diseases. Biomed Res Int 2014;2014:985408. http://dx.doi.org/10.1155/2014/985408.
[23] Bachrach L, Schwarz M, Warnke S, et al. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol 2019;114:19. https://doi.org/10.1007/s00395-019-0722-5.
[24] Deng J, Zhong Q. Advanced research on the microRNA mechanism in heart failure. Int J Cardiol 2016;220:61–4.
[25] McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005;115:538–46.
[26] Beggs Simon AS, Rørth R, Gardner Roy S, et al. Anticoagulation therapy potential interactions with skeletal muscle. Heart Fail Rev 2017;22:209–18.
[27] Aimo C, Castiglione V, Borrelli C, et al. Oxidative stress and inflammation in the evolution of heart failure: from pathophysiology to therapeutic strategies. Eur J Prev Cardiol 2020;27:494–510.
[28] van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006;103:18255–60.
[29] Yan H, Ma F, Zhang Y, et al. miRNAs as biomarkers for diagnosis of heart failure: a systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e6825. http://dx.doi.org/10.1097/MD. 0000000000006825.
[30] Vegeter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail 2016;18:457–68.
[31] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2125–32.
[32] Seronde MF, Vaught M, Gayet E, et al. Circulating microRNAs and outcome in patients with acute heart failure. PLoS One 2015;10:e0142237. https://doi.org/10.1371/journal.pone.0142237.
[33] Çakmak HA, Coskunpinar E, Íltemir B, et al. The prognostic value of circulating microRNAs in heart failure: preliminary results from a genome-wide expression study. J Cardiovasc Med (Hagerstown) 2015;16:431–7.
[34] Xiao J, Gao R, Bei Y, et al. Circulating miR-30d predicts survival in patients with acute heart failure. Cell Physiol Biochem 2017;41:865–74.

[35] Ovchinnikova ES, Schmitter D, Vegter EL, et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail 2016;18:414–23.

[36] Muthusamy S, DeMartino AM, Watson LJ, et al. MicroRNA-539 is up-regulated in failing heart, and suppresses O-GlcNAcase expression. J Biol Chem 2014;289:29665–76.

[37] Wang Y, Wang Q, Li C, et al. A review of Chinese herbal medicine for the treatment of chronic heart failure. Curr Pharm Des 2017;23:5115–24.

[38] Colpaert RMW, Calore M. MicroRNAs in cardiac diseases. Cells 2019;8:737. https://doi.org/10.3390/cells8070737.

[39] Bayoumi AS, Teoh JP, Aonuma T, et al. MicroRNA-532 protects the heart in acute myocardial infarction, and represses prss23, a positive regulator of endothelial-to-mesenchymal transition. Cardiovasc Res 2017;113:1603–14.

[40] Espinoza-Lewis RA, Wang DZ. MicroRNAs in heart development. Curr Top Dev Biol 2012;100:279–317.

[41] Huang Y, Gulsan K, Nguyen T, Wu Y. Biomarkers of cardiovascular disease. Circulation 2017;2017:2335–62.

[42] Zhang M, Cheng YJ, Sara JD, et al. Circulating microRNA-145 is associated with acute myocardial infarction and heart failure. Chin Med J (Engl) 2017;130:31–6.

[43] Huan T, Rong J, Tanriverdi K, et al. Dissecting the roles of microRNAs in coronary heart disease via integrative genomic analyses. Arterioscler Thromb Vasc Biol 2015;35:1011–21.